PDF(Pubmed)
Abstract：
We describe a rare case of polyserositis with chylous ascites following nivolumab therapy, highlighting the challenges in recognising and managing immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICPIs). Induced polyserositis and chylous ascites are very rare and require immunosuppressive treatment, with a variable response of high-dose IV steroids.
CONCLUSIONS: Oncological therapy with immune checkpoint inhibitors (ICPIs) is frequently associated with immune-related adverse events (irAEs) most involving cutaneous, gastrointestinal and pulmonary sites.
CONCLUSIONS: Oncological therapy with immune checkpoint inhibitors (ICPIs) is frequently associated with immune-related adverse events (irAEs) most involving cutaneous, gastrointestinal and pulmonary sites.
摘要：
我们描述了在nivolumab治疗后罕见的多浆膜炎伴乳糜腹水的病例，强调在识别和管理与免疫检查点抑制剂（ICPIs）相关的免疫相关不良事件（irAE）方面的挑战。诱导的多浆膜炎和乳糜腹水非常罕见，需要免疫抑制治疗，具有高剂量静脉注射类固醇的可变反应。
结论：使用免疫检查点抑制剂（ICPIs）的肿瘤治疗通常与最累及皮肤的免疫相关不良事件（irAE）相关。胃肠道和肺部部位。
结论：使用免疫检查点抑制剂（ICPIs）的肿瘤治疗通常与最累及皮肤的免疫相关不良事件（irAE）相关。胃肠道和肺部部位。
